상세정보 전남대학교 의학도서관

링크메뉴

주메뉴

상세정보

상세정보

검색결과 돌아가기

검색화면

부가기능

MARC보기

Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests [electronic resource] : workshop summary

상세 프로파일

상세정보
자료유형	e-Book
서명/저자사항	Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests: [electronic resource]: workshop summary / Sarah H. Beachy [and three others], Rapporteurs Roundtable on Translating Genomic-Based Research for Health Board on Health Sciences Policy.
개인저자	Beachy, speaker.
단체저자명	Institute of Medicine (U.S.).
발행사항	Washington, District of Columbia: National Academies Press, 2014.
발행사항	짤2014.
형태사항	1 online resource (102 pages) : illustrations, tables.
기타형태 저록	Print version: Refining processes for the co-development of genome-based therapeutics and companion diagnostic tests : workshop summary. Washington, District of Columbia : National Academies Press, c2014 xx, 82 pages 9780309298216
ISBN	9780309298223 0309298229
서지주기	Includes bibliographical references.
요약	Annotation.
초록	Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities-pharmaceutical and diagnostic companies-now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions.
주제명(지명)	United States. --fast
일반주제명	Drug development --United States --Congresses. Gene therapy --United States --Congresses. Therapeutics --United States --Congresses. MEDICAL / Pharmacology. Drug development. Gene therapy. Therapeutics.
분류기호(DDC)	615.19
언어	영어
바로가기

소장정보

소장정보

보존/밀집/기증 자료 신청 분관대출 서가부재도서 소장위치출력

메세지가 없습니다
No.	등록번호	청구기호	소장처	밀집번호	도서상태	반납예정일	예약	서비스	매체정보
1	E156313	EB 615.19	중앙도서관[본관]/E-Book/		대출가능				true\|true\|true\|false \|false\|true \|

초록

초록

초록 일부

초록 전체

Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission to the FDA of a companion diagnostic test.The co-development process, or the development of the test and drug for the simultaneous submission to FDA, has led to a major alteration in the way that drugs are being developed, with traditionally separate entities-pharmaceutical and diagnostic companies-now working in close collaboration. Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests is the summary of a workshop held by the Roundtable on Translating Genomic-Based Research for Health on February 27, 2013 to examine and discuss challenges and potential solutions for the codevelopment of targeted therapeutics and companion molecular tests for the prediction of drug response. Prior to the workshop, key stakeholders, including laboratory and medical professional societies, were individually asked to provide possible solutions to resolve the concerns raised about co-development of companion diagnostic tests and therapies. Workshop speakers were charged with addressing these solutions in their presentations by providing insight on (1) whether the proposed solutions address the problems described, (2) whether there are other solutions to propose, and (3) what steps could be taken to effectively implement the proposed solutions.